Table 3

Difference in mean DAS by time interval between those exposed to IVIg vs those currently unexposed, for all IVIg recipients as well for patients grouped by reason for IVIg

% CensoredMean difference (SEM); p value
TimeControl (n=49)SR (n=13)SD (n=16)Any IVIg vs controlSR vs controlSD vs controlIVIg-exposed SD vs IVIg-naive SD
<30 Days0003.167 (0.622); <0.00012.887 (0.645); <0.0001NANA
30 Days to 1 year000−0.777 (0.963); 0.42−1.317 (1.028); 0.200.398 (0.871); 0.650.3459 (0.421); 0.41
1–2 Years680−0.253 (0.513); 0.62−1.195 (0.526); 0.0231.751 (0.361); <0.0001−0.0784 (0.783); 0.92
2–3 Years18310−0.255 (0.554); 0.65−1.330 (0.404); 0.0010.885 (0.586); 0.13−0.8648 (1.041); 0.41
3–4 Years27380−0.449 (0.628); 0.48−1.667 (0.265); <0.00010.340 (0.888); 0.70−3.8539 (2.018); 0.044
4–5 Years434661.881 (1.185); 0.110.456 (0.293); 0.122.529 (1.561); 0.11
  • DAS, disease activity score; IVIg, intravenous immunoglobulin; SD, corticosteroid dependent; SR, corticosteroid resistant.